Becker's Healthcare September 21, 2022
Although biosimilars are usually cheaper than biologic brand-name drugs, a patient’s insurance plan can have a lot of sway in biosimilar drug prices, a recent study found.
Biosimilars are generic versions of biologic drugs, which have risen in cost over the years. These generics have been projected to save the U.S. $38.4 billion in biologic spending, but individual savings can differ if a patient isn’t a Medicare enrollee.
When comparing Medicare savings for chemotherapy drug Zarxio, a biosimilar approved by...
Today's Sponsors
Today's Sponsor